Skip to main content
LTRN
NASDAQ Life Sciences

Lantern Pharma Secures FDA IND for Pediatric Cancer Drug, Reports Strong LP-184 Phase 1a Data

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.235
Mkt Cap
$13.813M
52W Low
$1.11
52W High
$5.744
52W Position info
11% above low
Off High info
78% below high
Rel. Volume info
15× avg
Market data snapshot near publication time

LTRN is trading near its 52-week low of $1.11 (11% above the low) on elevated volume (15× avg).

Summary

Lantern Pharma announced significant clinical and regulatory advancements, including FDA IND clearance for STAR-001 through its Starlight Therapeutics subsidiary for a planned Phase 1 pediatric CNS cancer trial. The company also reported the successful completion of its LP-184 Phase 1a trial, achieving all primary endpoints with a 48% clinical benefit rate, and provided updates on LP-300 Phase 2 progress, including a Type C meeting package submission to the FDA. Additionally, LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, and the company introduced a new AI platform, withZeta.ai, with active beta testing and commercialization potential. These multiple positive milestones across its pipeline and AI platforms provide strong validation for Lantern Pharma's strategy and de-risk several programs, setting the stage for future value-creation catalysts. Investors will be watching for the outcome of the FDA Type C meeting for LP-300 and the initiation of planned Phase 1b/2 trials for LP-184.

At the time of this announcement, LTRN was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $1.11 to $5.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

LTRN - Latest Insights

LTRN
Nov 18, 2026, 8:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.3724
Real-time Price: $0.3601 info
Change: -$0.0123 (-3%) info
Market Cap: $5.377M info
LTRN
Nov 18, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3724
Real-time Price: $0.3601 info
Change: -$0.0123 (-3%) info
Market Cap: $5.377M info
LTRN
Nov 17, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.3601 info
Change: -$0.0049 (-1%) info
Market Cap: $5.377M info
LTRN
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.830
Real-time Price: $0.3601 info
Change: -$0.4699 (-57%) info
Market Cap: $5.377M info
LTRN
Oct 07, 2026, 8:31 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.3601 info
Change: -$0.5899 (-62%) info
Market Cap: $5.377M info